BIIB Q3 2022 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B-9.7% YoY

Gross Profit

$2.0B81.3% margin

Operating Income

$870M34.7% margin

Net Income

$1.1B45.2% margin

EPS (Diluted)

$7.84

QoQ Revenue Growth

-3.1%

Cash Flow

Operating Cash Flow

$661M

Free Cash Flow

$602M

Stock-Based Comp.

$64M

Balance Sheet

Total Assets

$24.9B

Total Liabilities

$12.1B

Stockholders' Equity

$12.8B

Cash & Equivalents

$3.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.8B	-9.7%
Gross Profit	$2.0B	$2.3B	-10.1%
Operating Income	$870M	$800M	+8.8%
Net Income	$1.1B	$329M	+244.7%

Revenue Segments

MS Product Revenues

$1.3B43%

TYSABRI product

$506M16%

Fumarate

$477M15%

SPINRAZA

$431M14%

Interferon

$336M11%

Geographic Segments

Non-US

$1.1B57%

UNITED STATES

$850M43%